Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2006 May-Jun;12(3):34-9.

The add-on effects of Gynostemma pentaphyllum on nonalcoholic fatty liver disease

Affiliations
  • PMID: 16708768
Randomized Controlled Trial

The add-on effects of Gynostemma pentaphyllum on nonalcoholic fatty liver disease

Shuo-Chi Chou et al. Altern Ther Health Med. 2006 May-Jun.

Abstract

Context: Other than weight reduction by dieting or physical activity, there are no well-documented medical treatments for fatty liver disease.

Objective: To evaluate the efficacy of the add-on Gynostemma pentaphyllum (GP) in research subjects with nonalcoholic fatty liver disease.

Design: A randomized, single-blind, controlled clinical trial.

Setting: Hospital-based clinic.

Patients: Fifty-six research subjects who were diagnosed with nonalcoholic fatty liver by abdominal ultrasound scanning.

Interventions: The treatment group and the control group followed a controlled diet for 2 months. After 2 months, the treatment group continued to diet and received 80 mL GP extraction for 4 months; the control group continued to diet and received a placebo capsule for 4 months.

Main outcome measures: Body mass index (BMI), biochemistry data, and fatty liver score were measured at baseline, at 2 months, and at 6 months.

Results: After 2 months of dieting, BMI and most biochemistry data decreased in both study groups. There were no significant differences in BMI or biochemistry data at month 2 between the 2 study groups. At month 6, BMI, triglyceride, aspartate aminotransferase (AST), alanine aminotransferase, alkaline phosphatase, insulin (ALP), insulin resistance index (HOMA-IR), and fatty liver score were reduced in both groups. The treatment group saw significant reductions in BMI, AST, ALP, insulin, and HOMA-IR, however. Changes in uric acid levels in the 2 groups from month 2 to month 6 were statistically significant (P = .028)

Conclusion: GP is an effective adjunct treatment to diet therapy for patients with nonalcoholic fatty liver disease.

PubMed Disclaimer

Publication types

LinkOut - more resources